Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 2/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | PLK1 | P53350 | 1/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.35 |
| ▸ | WNT3A | P56704 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6839318 | 0.92 | LMNA (0.49) | KDM4EALDH1A1LMNAHSD17B10MAPT | |
| SCHEMBL6839239 | 0.92 | LMNA (0.49) | KDM4EALDH1A1LMNAHSD17B10MAPT | |
| SCHEMBL15988845 | 0.89 | KDM4E (0.66) | KDM4EALDH1A1LMNAHSD17B10MAPT | |
| SCHEMBL6837756 | 0.88 | ALDH1A1 (0.43) | KDM4EALDH1A1LMNAHSD17B10MAPT | |
| SCHEMBL6199237 | 0.81 | MAPT (0.43) | KDM4EALDH1A1LMNAHSD17B10MAPT | |
| SCHEMBL19718022 | 0.78 | KDM4E (0.45) | KDM4EALDH1A1LMNAHSD17B10MAPT | |
| SCHEMBL30152314 | 0.78 | KDM4E (0.45) | KDM4EALDH1A1LMNAHSD17B10MAPT | |
| SCHEMBL15988872 | 0.78 | LMNA (0.59) | KDM4EALDH1A1LMNAHSD17B10MAPT | |
| SCHEMBL32889359 | 0.78 | LMNA (0.54) | KDM4EALDH1A1LMNAHSD17B10MAPT | |
| SCHEMBL8175292 | 0.77 | ALDH1A1 (0.39) | KDM4EALDH1A1LMNAHSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121758413-A | Preparation method of 1- (5-methoxy-2, 3-dihydro-1, 4-benzodioxane-8-yl) ethanone | 长沙贝塔医药科技有限公司 | 2026-03-31 | — | — | CN | disclosed |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230053726-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2023-02-23 | — | — | US | disclosed |
| US-9951053-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | SAMUMED, LLC (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170260176-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | MED-PATHWAYS II LIMITED (VG) | 2017-09-14 | — | — | US | disclosed |
| US-20170260176-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | MED-PATHWAYS II LIMITED (VG) | 2017-09-14 | — | — | US | disclosed |
| US-9533976-B2 | γ-diketones as WNT/β-catenin signaling pathway activators | SAMUMED, LLC (US) | 2017-01-03 | — | — | US | disclosed |
| EP-1110961-B1 | OXYGENIC HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KOGYO KK (JP) | 2004-07-14 | — | — | EP | disclosed |
| US-20010056117-A1 | Oxygen-containing heterocyclic compounds | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2001-12-27 | — | — | US | disclosed |
| US-6331542-B1 | TREATING DISEASES CHARACTERIZED BY BONE LOSS OR EXCESSIVE CARTILAGE OR MATRIX DEGRADATION | SMITHKLINE BEECHAM CORPORATION | 2001-12-18 | — | — | US | disclosed |
| US-6284777-B1 | BONE DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2001-09-04 | — | — | US | disclosed |
| EP-1110961-A1 | OXYGENIC HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-06-27 | — | — | EP | disclosed |
| US-6232342-B1 | CATHEPSIN K INHIBITOR FOR TREATING OSTEOPOROSIS, GINGIVITIS, PERIODONTITIS, ARTHRITIS, OSTEOARTHRITIS RHEUMATOID ARTHRITIS, PAGET'S DISEASE, HYPERCALCEMIA OF MALIGNANCY AND METABOLIC BONE DISEASES | SMITHKLINE BEECHAM CORPORATION | 2001-05-15 | — | — | US | disclosed |
| US-6057362-A | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-02 | — | — | US | disclosed |
| US-5998470-A | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0934291-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-08-11 | — | — | EP | disclosed |
| EP-0934291-A4 | — | SMITHKLINE BEECHAM CORP (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1997016433-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056117-A1 | Oxygen-containing heterocyclic compounds | CBR1, CBR3, MT-CO1 | KDM4E 444/4885ALDH1A1 232/4885LMNA 4242/4885 |
| US-20170260176-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | GSK3A, GSK3B, WNT1 | KDM4E 3701/4885ALDH1A1 1019/4885LMNA 1455/4885 |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | STAT6, STAT5B, STAT5A | KDM4E 444/4885ALDH1A1 3523/4885LMNA 4150/4885 |
| US-20230053726-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | GSK3A, GSK3B, WNT1 | KDM4E 3701/4885ALDH1A1 1019/4885LMNA 1455/4885 |
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | GSK3A, GSK3B, WNT1 | KDM4E 3614/4885ALDH1A1 1093/4885LMNA 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.